STANDARD BIOTOOLS INC (LAB) Stock Fundamental Analysis
USA - NASDAQ:LAB - US34385P1084 - Common Stock
1.2 USD
+0.05 (+4.35%)
1.2 USD
0 (0%)
Taking everything into account, LAB scores 2 out of 10 in our fundamental rating. LAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LAB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year LAB has reported negative net income.
LAB had a negative operating cash flow in the past year.
LAB had negative earnings in each of the past 5 years.
LAB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LAB has a worse Return On Assets (-21.64%) than 67.24% of its industry peers.
LAB has a worse Return On Equity (-28.38%) than 60.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.64% | ||
| ROE | -28.38% | ||
| ROIC | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 48.97%, LAB perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
LAB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
2. Health
2.1 Basic Checks
LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LAB has been increased compared to 1 year ago.
LAB has more shares outstanding than it did 5 years ago.
LAB has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.62, we must say that LAB is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.62, LAB is not doing good in the industry: 79.31% of the companies in the same industry are doing better.
LAB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, LAB is in the better half of the industry, outperforming 74.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.62 |
ROIC/WACCN/A
WACC10.68%
2.3 Liquidity
A Current Ratio of 5.16 indicates that LAB has no problem at all paying its short term obligations.
LAB has a Current ratio of 5.16. This is in the better half of the industry: LAB outperforms 72.41% of its industry peers.
A Quick Ratio of 4.92 indicates that LAB has no problem at all paying its short term obligations.
LAB's Quick ratio of 4.92 is fine compared to the rest of the industry. LAB outperforms 77.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.16 | ||
| Quick Ratio | 4.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 64.84% over the past year.
The Revenue has grown by 13.16% in the past year. This is quite good.
Measured over the past years, LAB shows a quite strong growth in Revenue. The Revenue has been growing by 8.28% on average per year.
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)13.16%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%12.79%
3.2 Future
The Earnings Per Share is expected to grow by 18.63% on average over the next years. This is quite good.
The Revenue is expected to decrease by -15.47% on average over the next years. This is quite bad
EPS Next Y59.6%
EPS Next 2Y31.32%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue Next Year-49.56%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.14%
Revenue Next 5Y-15.47%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LAB's earnings are expected to grow with 18.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.32%
EPS Next 3Y18.63%
5. Dividend
5.1 Amount
No dividends for LAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.2
+0.05 (+4.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners72.99%
Inst Owner ChangeN/A
Ins Owners2.54%
Ins Owner Change28.61%
Market Cap458.40M
Revenue(TTM)154.24M
Net Income(TTM)-120502000
Analysts77.14
Price Target1.81 (50.83%)
Short Float %3.18%
Short Ratio9.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.9%
Min EPS beat(2)-11.39%
Max EPS beat(2)7.59%
EPS beat(4)2
Avg EPS beat(4)-2.03%
Min EPS beat(4)-27.3%
Max EPS beat(4)22.99%
EPS beat(8)2
Avg EPS beat(8)-49.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.53%
Min Revenue beat(2)0.73%
Max Revenue beat(2)4.33%
Revenue beat(4)4
Avg Revenue beat(4)5.28%
Min Revenue beat(4)0.73%
Max Revenue beat(4)8.6%
Revenue beat(8)6
Avg Revenue beat(8)1.75%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.67%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-55.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.08 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.4
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.64% | ||
| ROE | -28.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.97% | ||
| FCFM | N/A |
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 78.73% | ||
| Cap/Sales | 8.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.16 | ||
| Quick Ratio | 4.92 | ||
| Altman-Z | -0.62 |
F-Score5
WACC10.68%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y59.6%
EPS Next 2Y31.32%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue 1Y (TTM)13.16%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%12.79%
Revenue Next Year-49.56%
Revenue Next 2Y-31.76%
Revenue Next 3Y-21.14%
Revenue Next 5Y-15.47%
EBIT growth 1Y4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.82%
EBIT Next 3Y24.48%
EBIT Next 5Y19.25%
FCF growth 1Y-61.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.78%
OCF growth 3YN/A
OCF growth 5YN/A
STANDARD BIOTOOLS INC / LAB FAQ
What is the ChartMill fundamental rating of STANDARD BIOTOOLS INC (LAB) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LAB.
What is the valuation status for LAB stock?
ChartMill assigns a valuation rating of 0 / 10 to STANDARD BIOTOOLS INC (LAB). This can be considered as Overvalued.
Can you provide the profitability details for STANDARD BIOTOOLS INC?
STANDARD BIOTOOLS INC (LAB) has a profitability rating of 0 / 10.
What is the earnings growth outlook for STANDARD BIOTOOLS INC?
The Earnings per Share (EPS) of STANDARD BIOTOOLS INC (LAB) is expected to grow by 59.6% in the next year.